The development of lurasidone for bipolar depression

Annals of the New York Academy of Sciences

Volumn 1358, Issue 1, 2015, Pages 95-104

  Loebel, Antony ^a   Xu, Jane ^a   Hsu, Jay ^a   Cucchiaro, Josephine ^a   Pikalov, Andrei ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Atypical antipsychotic; Bipolar disorder; Lurasidone; Major depressive episode

Indexed keywords

LITHIUM; LURASIDONE; VALPROIC ACID; NEUROLEPTIC AGENT;

AKATHISIA; ANXIETY DISORDER; ARTICLE; BIPOLAR DEPRESSION; CLINICAL RESEARCH; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MANIA; MONOTHERAPY; NAUSEA; NONHUMAN; PARKINSONISM; POST HOC ANALYSIS; RECEPTOR BINDING; RISK; SCHIZOPHRENIA; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; UNITED STATES; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG DEVELOPMENT;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG DISCOVERY; HUMANS; LURASIDONE HYDROCHLORIDE;

EID: 84958781047     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12965     Document Type: Article

References (56)

1. Merikangas, K.R., H.S. Akiskal, J. Angst, et al. 2007. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 64: 543-552.
2. Bebbington, P. & R. Ramana . 1995. The epidemiology of bipolar affective disorder. Soc. Psychiatry Psychiatr. Epidemiol. 30: 279-292.
3. Judd, L.L., H.S. Akiskal, P.J. Schettler, et al. 2002. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59: 530-537.
4. Calabrese, J.R., R.M. Hirschfeld, M.A. Frye & M.L. Reed . 2004. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sample. J. Clin. Psychiatry 65: 1499-1504.
5. Vos, T., A.D. Flaxman, M. Naghavi, et al. 2012. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2163-2169.
6. Fajutrao, J., J. Locklear, J. Priaulx & A. Heyes . 2009. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin. Pract. Epidemiol. Mental Health 5: 3.
7. Dean, B.B., D. Gerner & R.H. Gerner . 2004. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr. Med. Res. Opin. 20: 139-154.
8. Dilsaver, S.C. 2011. An estimate of the minimum economic burden of bipolar I and II disorders in the United States. J. Affect. Disord. 129: 79-83.
9. Hirschfeld, R.M., J.R. Calabrese, M.M. Weissman, et al. 2003. Screening for bipolar disorder in the community. J. Clin. Psychiatry 64: 53-59.
10. Daigneault, A., C. Duclos, S. Saury, et al. 2015. Diagnosis of bipolar disorder in primary and secondary care: what have we learned over a 10-year period? J. Affect. Disord. 174: 225-232.
11. Grant, B.F., F.S. Stinson, D.S. Hasin, et al. 2005. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 66: 1205-1215.
12. Merikangas, K.R., H.S. Akiskal, J. Angst, et al. 2007. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 64: 543-552.
13. Brady, K.T. & R.B. Lydiard . 1992. Bipolar affective disorder and substance abuse. J. Clin. Psychopharmacol. 12: 17S-22S.
14. Sonne, S.C., K.T. Brady & W.A. Morton . 1994. Substance abuse and bipolar affective disorder. J. Nerv. Ment. Dis. 182: 349-352.
15. Crump, C., K. Sundquist, M.A. Winkleby & J. Sundquist . 2013. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 70: 931-939.
16. Osby, U., L. Brandt, N. Correia, et al. 2001. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58: 844-550.
17. Mcintyre, R.S., J.Z. Konarski, V.L. Misener & S.H. Kennedy . 2005. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann. Clin. Psychiatry 2: 83-93.
18. Roshanaei-Moghaddam, B. & W. Katon . 2009. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr. Serv. 60: 147-156.
19. Fagiolini, A., K.N. Chengappa, I. Soreca & J. Chang . 2008. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 22: 655-669.
20. Vancampfort, D., K. Vansteelandt, C.U. Correll, et al. 2013. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am. J. Psychiatry 170: 265-274.
21. Sidor, M.M. & G.M. Macqueen . 2011. Antidepressants for the acute treatment of bipolar depression: a systematic review and metaanalysis. J. Clin. Psychiatry 72: 156-167.
22. Sienaert, P., L. Lambrichts, A. Dols & J. De Fruyt . 2013. Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. Bipolar Disord. 15: 61-69.
23. Van Lieshout, R.J. & G.M. MacQueen . 2010. Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. Br. J. Psychiatry 196: 266-273.
24. Baldessarini, R.J., L. Leahy, S. Arcona, et al. 2007. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr. Serv. 58: 85-91.
25. Goldberg, J.F., J.O. Brooks 3rd, K. Kurita, et al. 2009. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J. Clin. Psychiatry 70: 155-162.
26. Haeberle, A., W. Greil, S. Russmann & R. Grohmann . 2012. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry 12: 153.
27. Greil, W., A. Häberle, P. Haueis, et al. 2012. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J. Affect. Disord. 136: 534-542.
28. Cerullo, M.A. & S.M. Strakowski . 2013. A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectr. 18: 199-208.
29. Thase, M.E., A. Jonas, A. Khan, et al. 2008. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo controlled studies. J. Clin. Psychopharmacol. 28: 13-20.
30. Lombardo, I., G. Sachs, S. Kolluri, et al. 2012. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J. Clin. Psychopharmacol. 32: 470-478.
31. Sachs, G.S., K.S. Ice, P.B. Chappell, et al. 2011. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 72: 1413-1422.
32. Otsuka. 2014. Aripiprazole prescribing information. December 2014. Accessed October 1, 2015. http://www.otsuka-us.com/Documents/Abilify.PI.pdf.
33. U.S. Food and Drug Administration. 2009. Risperidone prescribing information. June 2009. Accessed October 1, 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056, 020588s044, 021346s033, 021444s03lbl.pdf.
34. Eli Lillly. 2015. Olanzapine-fluoxetine combination prescribing information. January 2015. Accessed October 1, 2015. http://pi.lilly.com/us/symbyax-pi.pdf.
35. Quetapine, X.R. 2013. Prescribing information. October 2013. Accessed October 1, 2015. http://www1.astrazeneca-us.com/pi/seroquelxr.pdf.
36. 1A receptor activity. J. Pharmacol. Exp. Ther. 334: 171-181.
37. Kroeze, W.K., S.J. Hufeisen, B.A. Popadak, et al. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526.
38. 2C receptor and antipsychotic-induced weight gain-mechanisms and genetics. J. Psychopharmacol. 20: 15-18.
39. 1A receptors. J. Pharmacol. Exp. Ther. 295: 853-861.
40. 7 receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern. Biol. Psychiatry 58: 831-837.
41. 7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51: 578-586.
42. 7 receptor subtype. Neuropharmacology 70: 211-217.
43. Stone, E.A., Y. Lin & D. Quartermain . 2008. Evaluation of the repeated open-space swim model of depression in the mouse. Pharmacol. Biochem. Behav. 91: 190e195.
44. Nasrallah, H.A., J. Cucchiaro, Y. Mao, et al. 2015. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectrums 20: 140-147.
45. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision. Washington, DC: American Psychiatric Association.
46. Loebel, A., J. Cucchiaro, R. Silva, et al. 2014. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 171: 160-168.
47. Loebel, A., J. Cucchiaro, R. Silva, et al. 2014. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 171: 169-177.
48. Suppes, T., J. Calabrese, R. Silva, et al. 2013. Lurasidone adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study (PREVAIL 3) [abstract No. W147]. Neuropsychopharmacology 38: S532-S533.
49. Ketter, T.A., K. Sarma, R. Silva, et al. 2014. Lurasidone in bipolar I depression: a 24-week, open-label extension study [abstract No. 17]. In Annual Meeting of the American Society of Clinical Psychopharmacology.
50. Nelson, J.C. & G.I. Papakostas . 2009. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 166: 980-991.
51. Iovieno, N. & G.I. Papakostas . 2012. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/ nonresponders with major depressive disorder? J. Clin. Psychiatry 73: 676-683.
52. Selle, V., S. Schalkwijk, G.H. Vázquez & R.J. Baldessarini . 2014. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 47: 43-52.
53. Nakamura, M., M. Ogasa, J. Guarino, et al. 2009. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo controlled trial. J. Clin. Psychiatry 70: 829-836.
54. Meltzer, H.Y., J. Cucchiaro, R. Silva, et al. 2011. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry 168: 957-967.
55. Nasrallah, H.A., R. Silva, D. Phillips, et al. 2013. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J. Psychiatr. Res. 47: 670-677.
56. Suppes, T., R. Silva, J. Cucchiaro, et al. 2015. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry. 2015 Nov 10:appiajp201515060770.